Societies Collaborate to Improve Scientific Exchange in UK Drug Discovery

A two-year strategic alliance between The European Laboratory Research & Innovation Group (ELRIG) UK and the British Pharmacological Society, offers each organisation the opportunity to expand its collaboration between industry, academia and the clinic, to help drive the successful discovery and development of new medicines across the UK.

With both groups committed to hosting joint and complementary meetings the alliance also facilitates each society to help grow its own audience and create exciting new opportunities for early career professionals’ education and training.

Steve Rees, Chairman of ELRIG UK, and VP of Discovery Biology at AstraZeneca, said: “The strategic alliance with the British Pharmacological Society formalises a joint goal of growth in the industrial and academic segments and recognises the harmonies between our organisations. Joining forces will help us improve education, networking and other services available to our communities, allowing us to become more impactful advocates for the life sciences industry.”

Professor Steve Hill, President of the British Pharmacological Society, and Professor of Molecular Pharmacology at the University of Nottingham, added: “We recognise that modern drug discovery is a multi-stakeholder process and that professionals are likely to move between sectors throughout the course of their working lives. It therefore makes sense for our programmes to represent all facets of drug discovery and we look forward to working with ELRIG UK to help achieve this goal.”

For further information about ELRIG UK, please visit: www.elrig.org,

For further information about the British Pharmacological Society, please visit: www.bps.ac.uk